Controversies in hepatitis C therapy: Reactivation of hepatitis B virus

Sarah R. Lieber; Michael W. Fried

doi:10.1002/cld.665

Controversies in hepatitis C therapy: Reactivation of hepatitis B virus

Research output: Contribution to journal › Review article › peer-review

Original language	English (US)
Pages (from-to)	87-92
Number of pages	6
Journal	Clinical Liver Disease
Volume	10
Issue number	4
DOIs	https://doi.org/10.1002/cld.665
State	Published - Oct 2017
Externally published	Yes

ASJC Scopus subject areas

Hepatology

Access to Document

10.1002/cld.665

Cite this

@article{d1764053c1764d148f8a1fadb7ccce02,

title = "Controversies in hepatitis C therapy: Reactivation of hepatitis B virus",

author = "Lieber, {Sarah R.} and Fried, {Michael W.}",

note = "Funding Information: Abbreviations: AASLD, American Association for the Study of Liver Diseases; ALT, alanine aminotransferase; DAA, direct-acting antiviral; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HBVr, hepatitis B reactivation; HCV, hepatitis C virus; IDSA, Infectious Diseases Society of America; IFN, interferon; IP-10, IFN-inducible protein 10; IST, immunosuppressive therapy; TNF, tumor necrosis factor; VL, viral load. From the Division of Gastroenterology and Hepatology, UNC Liver Center, University of North Carolina at Chapel Hill, Chapel Hill, NC. This study was supported by Grant T32DK07634 from the National Institutes of Health to S.R.L. Potential conflict of interest: Nothing to report. Received 24 May 2017; accepted 18 August 2017",

year = "2017",

month = oct,

doi = "10.1002/cld.665",

language = "English (US)",

volume = "10",

pages = "87--92",

journal = "Clinical Liver Disease",

issn = "2046-2484",

publisher = "John Wiley and Sons Ltd",

number = "4",

}

TY - JOUR

T1 - Controversies in hepatitis C therapy

T2 - Reactivation of hepatitis B virus

AU - Lieber, Sarah R.

AU - Fried, Michael W.

N1 - Funding Information: Abbreviations: AASLD, American Association for the Study of Liver Diseases; ALT, alanine aminotransferase; DAA, direct-acting antiviral; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HBVr, hepatitis B reactivation; HCV, hepatitis C virus; IDSA, Infectious Diseases Society of America; IFN, interferon; IP-10, IFN-inducible protein 10; IST, immunosuppressive therapy; TNF, tumor necrosis factor; VL, viral load. From the Division of Gastroenterology and Hepatology, UNC Liver Center, University of North Carolina at Chapel Hill, Chapel Hill, NC. This study was supported by Grant T32DK07634 from the National Institutes of Health to S.R.L. Potential conflict of interest: Nothing to report. Received 24 May 2017; accepted 18 August 2017

PY - 2017/10

Y1 - 2017/10

UR - http://www.scopus.com/inward/record.url?scp=85032917969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032917969&partnerID=8YFLogxK

U2 - 10.1002/cld.665

DO - 10.1002/cld.665

M3 - Review article

C2 - 31186893

AN - SCOPUS:85032917969

SN - 2046-2484

VL - 10

SP - 87

EP - 92

JO - Clinical Liver Disease

JF - Clinical Liver Disease

IS - 4

ER -

Controversies in hepatitis C therapy: Reactivation of hepatitis B virus

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this